Actemra, the brand name of tocilizumab, is for the treatment or rheumatoid arthritis that is severe in children. It is given intravenously.
Tocilizumab is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of RA in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. The drug is administered by monthly intravenous infusions. An infusion takes about an hour. Tocilizumab is used for the treatment of moderate to severe rheumatoid arthritis, applied in combination with methotrexate, if other drugs like disease-modifying antirheumatic drugs (DMARDs) and TNF alpha blockers have proven to be ineffective, or were not tolerated.
Contributions by Anypodetos, Rod57, and Carlo Banez.